Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the features and advantages of PHE885, a CAR-T therapy manufactured in less than two days, which allows the product to preserve T-cell stemness. The Phase I study (NCT04318327) reported an overall response rate (ORR) of 98%.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.